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Abstract The health effects of cosmic radiation on
astronauts need to be precisely quantified and controlled.
This task is important not only in perspective of the
increasing human presence at the International Space Sta-
tion (ISS), but also for the preparation of safe human
missions beyond low earth orbit. From a radiation protec-
tion point of view, the baseline quantity for radiation risk
assessment in space is the effective dose equivalent. The
present work reports the first successful attempt of the
experimental determination of the effective dose equivalent
in space, both for extra-vehicular activity (EVA) and intra-
vehicular activity (IVA). This was achieved using the
anthropomorphic torso phantom RANDO equipped with
more than 6,000 passive thermoluminescent detectors and
plastic nuclear track detectors, which have been exposed to
cosmic radiation inside the European Space Agency
MATROSHKA facility both outside and inside the ISS. In
order to calculate the effective dose equivalent, a numerical
model of the RANDO phantom, based on computer
tomography scans of the actual phantom, was developed. It
was found that the effective dose equivalent rate during an
EVA approaches 700 lSv/d, while during an IVA about
20 % lower values were observed. It is shown that the
individual dose based on a personal dosimeter reading for
an astronaut during IVA results in an overestimate of the
effective dose equivalent of about 15 %, whereas under an
EVA conditions the overestimate is more than 200 %. A
personal dosemeter can therefore deliver quite good
exposure records during IVA, but may overestimate the
effective dose equivalent received during an EVA
considerably.
Keywords Effective dose equivalent  International
Space Station  Space radiation environment  Space
dosimetry  Phantom experiments
Introduction
Astronauts living and working on-board the International
Space Station (ISS) at altitudes of about 400 km are
exposed to radiation levels that are up to two orders of
magnitude higher than at sea level. The main radiation
hazards are due to galactic cosmic radiation (GCR) and due
to protons and electrons of the radiation belt in the South
Atlantic Anomaly (SAA). GCR consists of 98 % protons
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and heavy ions (baryon component), with energies from
several tens up to 1012 MeV or more, and 2 % electrons
and positrons (lepton component). The baryon component
is composed of 87 % protons, 12 % helium ions (alpha
particles) and 1 % heavy ions. Inside the ISS, a secondary
radiation field with a significant contribution of neutrons is
produced, due to nuclear interactions of the GCR with the
atoms of the shielding material and the human body. The
contribution of these sources to the radiation hazard to
astronauts varies with the altitude, the solar activity and the
local shielding by the ISS itself (NCRP 2000).
In the ISS orbit of 50 inclination, the geomagnetic field
provides sufficient shielding to prevent high exposures due
to solar energetic particle events and hence tissue reactions
(deterministic effects). However, exposures by GCR may
cause stochastic effects such as cancer or effects on the
central nervous system. For determination of radiation risk
on human health, it is necessary to derive quality factors
and effective dose equivalent, which is the primary quan-
tity in evaluating risk for health detriments from ionizing
radiation in radiological protection in space. For this, one
needs to know both, absorbed doses and linear energy
transfer (LET) spectra in the organs of the body. Since
organ doses cannot be measured directly in humans, the
effective dose equivalent has to be determined by applying
a suitable anthropomorphic phantom equipped with
detector systems. Such a phantom was placed in the
European Space Agency (ESA) MATROSHKA (MTR)
facility (Reitz and Berger 2006; Dettmann et al. 2007),
which was designed and built under the leadership of the
German Aerospace Center (DLR). As phantom the RAN-
DO (The Phantom Laboratory, Salem, NY, USA) was
selected and equipped with a set of thermoluminescent
detectors (TLDs) and plastic nuclear track detectors
(PNTDs). The MATROSHKA facility was exposed for
more than 1 year outside, and further on two times inside
the ISS, thereby simulating an astronaut performing an
extra-vehicular activity (EVA) and an intra-vehicular
activity (IVA). Prior to these experiments, the effective
dose equivalent was only measured once, with the human
torso phantom Fred-1 placed inside the Space Shuttle
during the STS-91 mission to the Russian Space Station
MIR (Yasuda et al. 2000; Yasuda 2009), but was never
measured outside a spacecraft.
In the present paper, the NUmerical model of the
RANDO phantom (NUNDO) (Puchalska 2008) is repor-
ted as a suitable tool for organ dose and effective dose
equivalent calculations. The procedure of the organ dose
and the effective dose equivalent calculations is briefly
introduced for the three MATROSHKA experiments for
the years 2004 to 2009, outside and inside the ISS, based
on measurements of PNTDs and TLDs. PNTDs were
provided by the Oklahoma State University (OSU) and
analysed/evaluated by DLR; TLDs were provided and
analysed by the Institute of Nuclear Physics in Krakow,
Poland, the Institute of Atomic and Subatomic Physics in
Vienna, Austria, and DLR, Cologne, Germany. Whereas
the paper Reitz et al. (2009) suffered from limited data sets
(only doses and LET spectra for some organs are reported),
the present paper uses the latest TLD results based on the
publication Berger et al. (2013) and data from a complete
set of LET spectra measured in PNTDs and presents doses
for all organs and effective dose equivalents.
Materials and methods
The MATROSHKA facility
MATROSHKA is an ESA facility designed and built by
DLR and flown from 2004 to 2011 on-board the ISS (Reitz
and Berger 2006; Dettmann et al. 2007). MATROSHKA
was designed to estimate the organ doses to astronauts
inside the ISS and during an EVA, in order to improve the
assessment of radiation risks in future space missions. For
this purpose, an anthropomorphic human phantom (RAN-
DO), typically used in radiotherapy for dose verification,
equipped with numerous radiation detectors (including
TLDs (1,634 measurement points), NTDPs, silicon detec-
tors, scintillators and a tissue equivalent proportional
counter), and was exposed outside the Russian module
Zvezda from 26 February 2004 up to 18 August 2005. This
phase of the experiment was called MATROSHKA-1
(MTR-1). A carbon fibre container, with an average mass
shielding of *0.5 g/cm2, simulated the shielding distri-
bution of an astronaut’s EVA suit. The second and the third
phases of the experiment were performed inside two dif-
ferent segments of the ISS, the Pirs Docking Compartment
(MTR-2A) and the Zvezda Service Module (MTR-2B),
from 5 January 2006 to 7 December 2006 and from 18
October 2007 to 18 March 2009, respectively (Berger et al.
2013). In the present paper, only data from TLDs and
NTDPs are reported.
The RANDO phantom
The RANDO phantom is an upper torso made of a natural
human skeleton embedded in a tissue equivalent material
(polyurethane) simulating soft and muscle tissues
(ZEff = 7.4; q = 1.05 g/cm
3). Polyurethane has an effec-
tive atomic number of 7.6 and a mass density of
0.997 g/cm3. A material with a lower effective atomic
number of 7.1 and almost three times lower mass density,
equal to 0.352 g/cm3, was used to simulate the lungs
(ZEff = 7.4; q = 0.32 g/cm
3). The phantom torso is 84 cm
in height with a maximal width of 40 cm and a maximal
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depth of 22 cm. The phantom torso is shown in Fig. 1a,
and the element composition is given in Table 1.
Modelling of the numerical RANDO phantom
(NUNDO)
The innovative part of this work was development of the
numerical voxel model NUNDO of the RANDO phantom
and its application to organ dose calculations. For this
purpose, computer tomography (CT) scans of the RAN-
DO phantom were performed (see Fig. 1b). A region-of-
interest routine, implemented in the public domain JavaTM
image processing and analysis software ImageJ (Schneider
et al. 2012), was used for image segmentation into clusters
representing bones, lungs and soft tissues, and to fill each
organ with a unique index value. Thus, the organ index
Fig. 1 a Front view of RANDO phantom; b CT scan of the phantom; c and d the numerical voxel phantom NUNDO; organs and tissues are
represented by different colours, and not all organs are visible
Table 1 Element composition
(percentage by weight) of the
RANDO phantom (The
Phantom Laboratory, Salem,
NY, USA)
Element Soft tissue Lungs
Carbon 67.78 70.74
Oxygen 20.31 21.28
Hydrogen 9.18 5.97
Nitrogen 2.50 1.9
Antimony 0.22 0.1
Table 2 Mass of the NUNDO phantom organs compared to the ICRP
reference man (ICRP 2002)
Organ Mass (g)
NUNDO ICRP 2002
Bladder 45 50
Brain 1,239 1,450
Breast 25 25
Colon 322 370 (73)
Oesophagus 34 40 (6)
Gonads 31 35 (12)
Heart 344 330 (55)
Kidneys 302 310 (80)
Liver 1,623 1,800 (390)
Lungs 1,720 1,200 (322)
Pancreas 128 140 (39)
Salivary glands 72 85
Small intestines 613 650 (78)
Spleen 157 150 (44)
Stomach 159 150 (46)
Thymus 24 25 (9)
Thyroid 19 20 (7)
In brackets, if available, the standard deviations for populations are
shown (ICRP 2002)
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image was achieved containing a 401 by 401 matrix, in
which the Hounsfield numbers (Hounsfield 1973) were
replaced by integers corresponding to the organ index
value. For each CT slice, a file was created and named by
the slice number. The final voxel model is then a three-
dimensional array of 401 by 401 by 169 voxels, in which
the resolution in the transversal plane is 1 mm per pixel
and in the vertical plane is 5 mm per pixel. The total
number of voxels is equal to 2.7 9 107.
Since the physical RANDO phantom does not contain
all the specific radiosensitive organs and tissues given by
ICRP Report 103 (2007), the soft tissue material was
replaced by the corresponding organs. This was performed
by scaling the organs from the human phantom Zubal
(Zubal et al. 1994) to the dimensions of the RANDO
phantom. The NUNDO model is shown in Fig. 1c, d.
Table 2 compares the masses of the defined organs of
the NUNDO voxel phantom, calculated by multiplying the
volume of the voxel organs and their mass densities, with
the ICRP Reference Man values (ICRP 2002). Using the
skin density of approximately 1.1 g/cm3, the reference
body surface area of 1.90 m2 and the total skin mass of
3,300 g for the reference male, the reference skin thickness
(epidermis and dermis) can be estimated to be approxi-
mately 1.6 mm for the adult male (ICRP 2009). Hence, the
skin of the NUNDO phantom is represented by 2 voxel
layers, of 1 mm each, wrapping the phantoms’ exterior.
Note that in Reitz et al. (2009), the skin thickness was
3 mm, following the medical sources.
The agreement for the inner organs, except lungs, with the
Reference Man (ICRP 2002) is very good. A larger differ-
ence was observed for the lungs (*40 %), which is the result
of the individual diversity for population. The RANDO
phantom’s lung material closely mimics the density of lungs
in a median respiratory state. The moulded lungs are hand-
shaped and fitted to naturally fill the rib cage. Natural human
skeletons are used, which are not always of the same size and
shape. Also, many skeletons reflect natural human charac-
teristics such as lack of symmetry and distorted joints (The
Phantom Laboratory, Salem, NY, USA).
Detector systems
The RANDO phantom is built up of 33 slices with a
thickness of 2.5 cm each. In each slice horizontal cut-outs
were milled to accommodate up to 5,800 TLDs fixed in
polyethylene tubes. A total of 354 tubes allow a total
number of 1,634 measurement positions inside the phan-
tom, arranged in a way that the TLDs are positioned in a
2.54-cm orthogonal grid. The phantom was covered by a
Nomex hood and poncho, which were also filled with TL
detectors to calculate skin doses. TLDs are used to deter-
mine the dose for radiation with an LET below 10 keV/lm,
where the TLD efficiency is equal to unity (Berger and
Hajek 2008). The dose in the entire relevant high-LET
range above 10 keV/lm can be measured by PNTDs with
high efficiency. The combination of the passive TLDs and
PNTDs is a commonly used technique in space dosimetry
(Reitz 1994; Benton et al. 2002; Vanhavere et al. 2008;
Straube et al. 2010). Due to limited space inside the
phantom, detector packages containing PNTDs and TLDs
were placed inside polyethylene boxes only at positions of
selected organs and in the poncho. Data obtained with
these detectors were used to calculate the relevant quality
factors. The respective procedure is given in Reitz et al.
(2009), where the PNTD data were provided by Johnson
Space Center (NASA-JSC). The data from PNTDs pre-
sented here were determined from the detectors provided
by OSU and evaluated and analysed at DLR.
Within the MATROSHKA facility, all participating
laboratories providing data for the phantom depth dose
distribution used TLDs based on lithium fluoride, activated
with magnesium and titanium (7LiF:Mg,Ti). The measured
signals were converted to units of absorbed dose in water
through calibrations performed with secondary-standard
gamma-ray radiation sources (60Co and 137Cs). The
parameters for the detector preparations, readout and the
quantification method of the TL signal are given in Reitz
et al. (2009) and Berger et al. (2013).
The long-term stability of the TLD signal (fading) was
studied by Bilski et al. (2013). The results revealed that for
the properly oven-annealed LiF-TLDs, fading is not a
significant problem. For measuring periods longer than a
year, almost all measured doses were within 10 % devia-
tion from the true values, while more than 80 % of the
results show deviations smaller than 5 %.
Three-dimensional dose distribution model
Three-dimensional (3D) continuous dose distribution
models were created by interpolating between 1,634 dis-
crete measured grid points (measured with TLDs in a 2.5-
cm grid) (Berger et al. 2013). For interpolation, the inverse
distance-weighted method, based on Shepard’s method
(Shepard 1968) applying Liszka’s modifications (Liszka
1984), was used. This interpolation method is based on the
assumption that the interpolated value should be influenced
most by the nearby points and less by the more distant
points. The dose at point i, Di, is the weighted average of
grid point doses and is calculated by:
Di ¼
PN
j¼1
wj  Dj
PN
j¼1
wj
ð1Þ
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where N is the number of grid points, Dj is the dose value at
grid point j and wj is a weight factor assigned to each grid
point expressed by:
wj ¼ 1
ðR2j þ d2Þ
b
2
ð2Þ
where b is a positive real number controlling the smooth-
ness of interpolation (b = 2 by default), Rj is the distance
between the grid point and the interpolated point and d2 is
the measurement error (7 %). The weight assigned to each
grid point diminishes as the distance from the interpolated
point increases. The weight factor is normalized and thus
that the weights sum up to unity.
Due to the high contribution of low-energetic electrons
for the less shielded MTR-1 EVA exposure, a steep dose
gradient from the skin layer towards the inner-body layers
of around 80 % was observed (Reitz et al. 2009). Hence,
for the interpolation from the measurement of the body
layer to the first measuring point inside the phantom, an
exponential attenuation function was adopted:
Di ¼ Dj þ Dskin  exp x0  Rj
t
 
ð3Þ
where x0 and t are parameters determining the slope of the
dose decrease (x0 = -0.16; t = 1.26), Dskin and Dj are the
doses measured at the body surface and at the closest mea-
surement point inside the phantom (*1 cm), respectively.
Calculation of organ dose
Combining the 3D continuous dose distribution model and
the NUNDO voxel model phantom, an average dose to the
organ T was calculated according to Eq. 4.
DT ¼
PNT
i¼1
Di
NT
ð4Þ
Table 3 Average TLD organ
dose rates for the whole LET
spectrum and for LET\10 keV/
lm (DTDL and DTDL-low,
respectively), average PNTD
organ dose rates for LET
[10 keV/lm (DPNTD-high) and
total average organ dose rates
(DT); total average organ dose
equivalent rates for the whole
LET spectrum and for LET
[10 keV/lm (HT and HPNTD-
high, respectively) and mean
quality factors (QT ) for organs
and locations where
combination of TLDs and
PNTDs were applied
PNTD data from detectors
provided by OSU and
evaluated/analysed by DLR
Relative precisions for dose rate
values range between 4 and 8 %
and for dose equivalent rate and
Q values around 15 %
DTLD
(lGy/d)
DTLD-low
(lGy/d)
DPNTD-high
(lGy/d)
DT
(lGy/d)
DT/
DTLD
HPNTD-
high
HT
(lSv/d)
QT
(lSv/d)
MTR-1
Eye 527 507 37 544 1.03 479 986 1.8
Lung 266 252 27 279 1.05 407 659 2.4
Stomach 226 209 30 239 1.06 432 641 2.7
Kidney 199 186 23 209 1.05 313 499 2.4
Small
Intestine
220 204 29 233 1.06 418 622 2.7
Skin 1,319 1,229 150 1,379 1.05 1,796 3,025 2.2
Poncho 587 497 150 647 1.10 1,796 2,293 3.5
MTR-2A
Eye 209 193 28 221 1.06 381 574 2.6
Lung 181 165 28 193 1.07 391 556 2.9
Stomach 163 148 29 177 1.09 434 582 3.3
Kidney 154 142 22 164 1.07 329 471 2.9
Small
Intestine
161 147 26 173 1.07 401 548 3.2
Skin 214 197 31 228 1.07 444 641 2.8
Poncho 223 205 31 236 1.06 444 649 2.8
MTR-2B
Eye 173 156 30 186 1.08 396 552 3.0
Lung 172 155 30 185 1.08 430 585 3.2
Stomach 160 142 31 173 1.08 410 552 3.2
Kidney 168 150 30 180 1.07 393 543 3.0
Small
Intestine
166 148 30 178 1.07 398 546 3.1
Skin 177 156 36 192 1.08 487 643 3.3
Poncho 173 152 36 188 1.09 487 639 3.4
Radiat Environ Biophys (2014) 53:719–727 723
123
where Di is the dose value at point i that corresponds to a
voxel i representing the organ T with the maximal number
of voxels NT.
The TLD readings were corrected by subtracting the
dose calculated from the LET spectra measured by the
PNTDs for LET [10 keV/lm and weighted with the
response function of the TLDs (Reitz et al. 2009). Each
dose value Di was calculated as the sum of the corrected
experimental TLD absorbed dose and the dose calculated
from the appropriate PNTD LET spectra. For other radio-
sensitive organs, where PNTD data were not available, an
average correction factor of 1.07 was applied to the TLD
measurements, based on the average ratio of the total organ
dose measured with the combined TLD-PNTD method and
the TLD organ dose (see Table 3).
Calculation of effective dose equivalent
The effective dose, E, is the sum of the equivalent doses,
HT, in all the radiosensitive organs T, weighted by a
dimensionless tissue weighting factor wT that represents
the relative contribution of the organ to the total detriment
E ¼
X
T
wT  HT: ð5Þ
For radiation protection in space, the non-measurable
equivalent doses are replaced by the organ dose equivalent
HT (ICRU 1993; NCRP 2000; ICRP 2013) which is cal-
culated as a mean value over the whole organ of interest
based on calculation of a dose equivalent at a point.
HT ¼
Z
L
Q ðLÞdDT ðLÞ ð6Þ
where dDT (L) is the contribution to the absorbed dose
from a radiation component with an LET between L and
L ? dL and Q (L) is a dimensionless mean quality factor
(ICRP 1991). Applying the organ dose equivalent, the
respective quantity as defined in ICRP Report 123 (ICRP
2013) is henceforth called effective dose equivalent.
For these calculations, the wT values were taken from
the ICRP Recommendation 60 (ICRP 1991), which cur-
rently forms the basis of the EU legal radiation protection
regulations. In 2007, a revised set of wT values, selected by
judgement on the basis of a broad range of experimental
data, has been published in the ICRP Recommendation 103
(ICRP 2007). The changes in the tissue weighting factor wT
made by the Commission are as follows: the value for the
breast increased from 0.05 to 0.12; that for gonads
decreased from 0.20 to 0.08; those for bladder, oesophagus,
liver and thyroid decreased from 0.05 to 0.04; a value of
0.12 is given in place of 0.05 for the remainder tissues; and
an additional value of 0.01 is given for the brain and the
salivary glands. In order to visualize the effect of these
changes, in the present paper the effective dose equivalent
was calculated using both, ICRP (1991) wT values and
ICRP (2007) wT values.
The mean quality factors in selected organs, where
PNTDs were applied, were calculated as the ratio between
the total dose equivalent and the total organ dose (see Reitz
et al. (2009) for details). For the calculation of the mean
quality factors in all remaining organs, an interpolation was
performed using the Q values received by LET spectra
measurement in the selected organs, applying the mean
shielding depth for the organs of interest in the NUNDO
phantom (Matthia¨ et al. 2013).
Results and discussion
The combined TLDs and PNTDs’ data for the MTR-1/2A/
2B experiments for the organs and for the poncho detec-
tors, which act as surrogate for a personal dosemeter of an
astronaut, are presented in Table 3.
The average TLD organ dose rate calculated by folding
the TLD 3D dose distribution model with the NUNDO
voxel phantom (Fig. 2) is given by DTLD. DTLD-low rep-
resents the average absorbed organ dose rate measured by
TLDs for LET \10 keV/lm, and the DPNTD-high repre-
sents the absorbed dose rate measured by PNTDs for LET
[10 keV/lm. DT is the total average organ dose rate
given by the sum of DTLD-low and DPNTD-high. The total
daily organ dose equivalent rate (HT) and the mean
quality factor (QT) are based on the combination of TLD
measurements and PNTD data. (see Reitz et al. 2009 for
further details).
The mean quality factor ranges from 2.2 for the skin to
2.7 for stomach and small intestine for MTR-1. For MTR-
2A, the mean quality factor for the skin is 2.8, while it is
3.3 for the stomach. For the MTR-2B exposure, the mean
quality factors are quite homogenous and close to 3.1. The
mean quality factor for stomach for MTR-1 agrees well
with the value calculated by Zhou et al. (2010) based on
NASA-JSC detectors.
The average organ dose rates, the average dose equiv-
alent rates and the mean quality factors for all the radio-
sensitive organs, given by ICRP Report 103 (2007), for the
MTR-1/2A/2B phantom torso experiments are summarized
in Table 4.
The results show a very steep, around 80 %, dose rate
decrease from the skin (1,379 ± 79 lGy/d) towards the
inner organs for MTR-1. This decrease is most pronounced
in the lower part of the phantom (stomach, bladder) which
is a consequence of higher body self-shielding and addi-
tional bottom shielding from the ISS.
724 Radiat Environ Biophys (2014) 53:719–727
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Fig. 2 Continuous TLD dose distribution models combined with the numerical voxel phantom NUNDO for a MTR-1, b MTR-2A and c MTR-
2B. Mean organ dose rates are calculated from these distributions (Tables 3, 4)
Table 4 Average organ dose rates (DT), average organ dose equivalent rates (HT) and the mean quality factors (QT ) calculated for all
radiosensitive organs for MTR-1/2A/2B phantom torso facilities
Organ DT (lGy/d) QT HT (lSv/d)
MTR-1 MTR-2A MTR-2B MTR-1 MTR-2A MTR-2B MTR-1 MTR-2A MTR-2B
Bladder 225 ± 13 173 ± 10 182 ± 10 2.4 ± 0.4 2.9 ± 0.4 3.1 ± 0.5 546 ± 82 507 ± 76 569 ± 85
Stomach 239 ± 14 177 ± 10 173 ± 10 2.7 ± 0.4 3.3 ± 0.5 3.2 ± 0.5 641 ± 96 582 ± 87 552 ± 83
Colon 245 ± 14 176 ± 10 181 ± 10 2.6 ± 0.4 3.2 ± 0.5 3.1 ± 0.5 636 ± 95 557 ± 84 565 ± 85
Red bone marrow 247 ± 14 180 ± 10 185 ± 11 2.5 ± 0.4 3.0 ± 0.5 3.1 ± 0.5 615 ± 92 543 ± 81 578 ± 87
Liver 250 ± 14 176 ± 10 178 ± 10 2.7 ± 0.4 3.3 ± 0.5 3.1 ± 0.5 669 ± 100 583 ± 87 557 ± 83
Reminder 260 ± 15 181 ± 10 179 ± 10 2.4 ± 0.4 2.9 ± 0.4 3.1 ± 0.5 618 ± 93 522 ± 78 559 ± 84
Oesophagus 275 ± 16 184 ± 11 178 ± 10 2.5 ± 0.4 3.0 ± 0.5 3.1 ± 0.5 691 ± 104 560 ± 84 556 ± 83
Lungs 279 ± 16 193 ± 11 185 ± 11 2.4 ± 0.4 2.9 ± 0.4 3.2 ± 0.5 659 ± 99 556 ± 83 585 ± 88
Bones 285 ± 16 190 ± 11 186 ± 11 2.4 ± 0.4 2.9 ± 0.4 3.1 ± 0.5 691 ± 104 558 ± 84 582 ± 87
Gonads 287 ± 16 183 ± 10 180 ± 10 2.2 ± 0.3 2.8 ± 0.4 3.1 ± 0.5 641 ± 96 512 ± 77 562 ± 84
Thyroid 316 ± 18 203 ± 12 180 ± 10 2.3 ± 0.3 2.9 ± 0.4 3.1 ± 0.5 736 ± 110 580 ± 87 564 ± 85
Brain 318 ± 18 199 ± 11 188 ± 11 2.3 ± 0.3 2.8 ± 0.4 3.1 ± 0.5 724 ± 109 561 ± 84 588 ± 88
Salivary glands 355 ± 20 203 ± 12 183 ± 11 2.3 ± 0.3 2.8 ± 0.4 3.1 ± 0.5 809 ± 121 571 ± 86 572 ± 86
Breast 485 ± 28 200 ± 11 179 ± 10 2.3 ± 0.3 2.8 ± 0.4 3.1 ± 0.5 1,107 ± 166 565 ± 85 559 ± 84
Skin 1,379 ± 79 228 ± 13 192 ± 11 2.2 ± 0.3 2.8 ± 0.4 3.3 ± 0.5 3,025 ± 453 641 ± 96 643 ± 97
For all organs, except lungs, skin and stomach, the DT values were calculated by multiplying the TLD doses by an average correction factor of
1.07 (DT/DTLD in Table 3). One-sigma uncertainties were calculated by error propagation
Radiat Environ Biophys (2014) 53:719–727 725
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The calculated dose rate for the skin for intra-vehicular
exposure with MTR-2A (Pirs module) is 228 ± 13 lGy/d.
In this case, the dose rate decrease from the skin towards
the deeper located organs is\25 %. In contrast, for MTR-
2B it is hard to see a decrease in dose rate towards the inner
organs. The average skin dose rate for MTR-2B was cal-
culated as 192 ± 11 lGy/d, which is approximately 15 %
less than the average skin dose for MTR-2A. The differ-
ence in dose rate in the two different modules of the ISS
results from a complex interplay of solar activity and
shielding thickness: MTR-2B was exposed at lower solar
activity than MTR-2A, which means that there was a
higher contribution to the dose from the protons of the
radiation belts and from GCR; on the other hand, the
thicker shielding in case of MTR-2B compared with MTR-
2A reduced the dose contributed by protons from the
radiation belt. Deeper within the phantom, the solar mod-
ulation dominates any differences in dose, whereas closer
to the surface of the phantom the shielding of the ISS
module dominates, resulting in higher doses for MTR-2A
(Berger et al. 2013).
Effective dose equivalent rates calculated either with wT
values from ICRP Recommendation 60 (ICRP 1991) or
with those from ICRP Recommendation 103 (ICRP 2007)
are shown in Table 5. The effective dose equivalent rate
during an EVA (MTR-1) is 690 ± 33 lSv/d applying the
wT values from ICRP Report 60 and 722 ± 35 lSv/d when
using wT values from ICRP Report 103. In contrast,
effective dose equivalent rates calculated for an IVA at
different ISS modules based on ICRP Report 60 are
549 ± 27 lSv/d for MTR-2A and 566 ± 29 lSv/d for
MTR-2B; while based on ICRP Report 103, they are
552 ± 26 lSv/d for MTR-2A and 566 ± 27 lSv/d for
MTR-2B. For comparison, the effective dose equivalent
rate onboard the vehicle during the short-term STS-91
mission was calculated as 418 lSv/d using wT values based
on ICRP Report 60 and 408 lSv/d using the ICRP Report
103 wT values (Yasuda 2009). The small differences, 5 %
for MTR-1 and \1 % for MTR-2A/B, in effective dose
equivalent rate calculated based on ICRP Reports 60 and
103, demonstrate that the update of wT values by ICPR 103
does not affect much the radiation risk estimates for sto-
chastic effects in astronauts.
Worth emphasizing is that the 15 % increase in the skin
dose for MTR-2A compared to MTR-2B does not con-
tribute much to the total effective dose equivalent for
MTR-2A, as the contribution of the skin to the effective
dose equivalent is only 1 %.
The use of the poncho detector set (HT values from
Table 3), a surrogate of a personal dosimeter worn by an
astronaut, would overestimate the effective dose equivalent
(Table 5) for an IVA by about a factor of 1.18 for MTR-2A
and 1.13 for MTR-2B. During an EVA (MTR-1), the over-
estimation becomes larger than a factor of 3. When comparing
the calculated here effective dose equivalent to the dose
equivalent in the poncho detectors measured by NASA-JSC
detectors (Zhou et al. 2010), this factor is about 1.9. The dif-
ference can be explained by the fact that the OSU/DLR
detectors reported here were located at the outer surface of the
detector package, thus representing a surrogate of a personal
dosimeter, whereas the NASA-JSC detectors experienced an
additional shielding of about 9.5 mm of plastic as they were
located at the lower surface of the respective package.
Conclusions
For the first time, a human torso phantom equipped with
radiation detectors was used as part of the MATROSHKA
facility to measure the doses at several locations inside and
on the ‘skin’ of the phantom, which has been mounted
outside the ISS simulating an astronaut during EVA. Fol-
lowing the outside exposure two measurement campaigns
were performed inside the Russian modules of the ISS
(Zvezda and Pirs). The measured depth dose profiles were
combined with a numerical voxel model of the RANDO
phantom (called NUNDO), in order to calculate organ and
effective dose equivalents.
The main result of the present work is the depth dose
profiles inside the phantom in the different exposure
locations, which may be used to benchmark space radiation
models and radiation transport calculations required for
mission planning. Outside the station the depth dose gra-
dient from the skin to the inner organs is very steep,
demonstrating that measurements of a personal dosimeter
dramatically overestimate the exposure of an astronaut, in
the worst case by a factor of more than three. Exposures
inside do not show this dramatic effect, but as lower the
shielding thickness in inside exposures as steeper the gra-
dient becomes. In the Pirs module (MTR-2A), the over-
estimation is about a factor of 1.18, whereas in the heavier
shielded Zvezda module (MTR-2B) the overestimate is
only a factor of 1.13.
Table 5 Effective dose equivalent rates for wT values taken from
ICRP Report 60 (ICRP 1991) and from ICRP Report 103 (ICRP
2007)
E (lSv/d)
(ICRP 1991) (ICRP 2007)
MTR-1 690 ± 33 722 ± 35
MTR-2A 549 ± 27 552 ± 26
MTR-2B 566 ± 29 566 ± 27
One-sigma uncertainties were calculated by error propagation
726 Radiat Environ Biophys (2014) 53:719–727
123
Furthermore, it was shown that already in an outside
exposure the self-shielding of the human body is very
effective. The exposure of the various inner organs is
comparatively homogeneous, and the effective dose
equivalent is only less than 30 % higher than in an inside
exposure.
So far, most of the measurements were performed with
passive detector systems that do not provide time-resolved
information. Therefore, future efforts aim at continuing
with time-resolved measurements, to record the temporal
pattern of the organ doses. In addition the results obtained
so far are representing exposures at times of rather low
solar activity. Accordingly, future measurements are
planned at times of high solar activities, and the potential
change of the depth dose distribution due to solar particle
events should also be investigated. Note that solar particle
events were absent during the measurement campaigns of
the MTR facility.
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